These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30205105)

  • 41. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
    J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of benign prostatic hyperplasia.
    Nunes RV; Manzano J; Truzzi JC; Nardi A; Silvinato A; Bernardo WM;
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):95-99. PubMed ID: 28355368
    [No Abstract]   [Full Text] [Related]  

  • 43. [Applying bladder outlet obstruction number to predict bladder outlet obstruction of benign prostatic hyperplasia].
    Zhang P; Wu ZJ; Yang Y; Zhang XD
    Zhonghua Wai Ke Za Zhi; 2008 Aug; 46(15):1156-9. PubMed ID: 19094679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?
    Reynard JM
    Curr Opin Urol; 2004 Jan; 14(1):13-6. PubMed ID: 15091043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of Bladder Dysfunction in Men with Lower Urinary Tract Symptoms Refractory to Alpha-blocker Therapy: A Video-urodynamic Analysis.
    Jiang YH; Liao CH; Kuo HC
    Low Urin Tract Symptoms; 2018 Jan; 10(1):32-37. PubMed ID: 27366877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy.
    Campbell J; Reid J; Ordon M; Welk B
    Urology; 2019 Aug; 130():126-131. PubMed ID: 31129193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha adrenoceptor antagonists in the year 2000: is there anything new?
    Chapple CR
    Curr Opin Urol; 2001 Jan; 11(1):9-16. PubMed ID: 11148741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preliminary results of a randomized crossover clinical trial comparing a new electromagnetic and vibrating device and alpha-blocker agents in patients affected by bladder outlet obstruction secondary to benign prostatic hyperplasia.
    Brardi S; Romano G; Cevenini G
    Arch Ital Urol Androl; 2021 Dec; 93(4):501-504. PubMed ID: 34933545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms.
    Lemack GE
    Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351
    [No Abstract]   [Full Text] [Related]  

  • 53. Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
    Watanabe Y; Yokoyama T; Ozawa H; Nishiguchi J; Nose H; Kumon H
    Urol Int; 2004; 73(3):252-7. PubMed ID: 15539846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment.
    Jiang YH; Wang CC; Kuo HC
    PLoS One; 2018; 13(2):e0190704. PubMed ID: 29462145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benign prostatic hyperplasia - progress in pathophysiology and management.
    Dobrek Ł; Thor PJ
    Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?
    Lee KS; Lee HW; Han DH
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):491-501. PubMed ID: 18172610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.
    Homma Y; Gotoh M; Kawauchi A; Kojima Y; Masumori N; Nagai A; Saitoh T; Sakai H; Takahashi S; Ukimura O; Yamanishi T; Yokoyama O; Yoshida M; Maeda K
    Int J Urol; 2017 Oct; 24(10):716-729. PubMed ID: 28748576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction.
    Baldwin KC; Ginsberg PC; Harkaway RC
    Urol Int; 2001; 66(2):84-8. PubMed ID: 11223749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence?
    Dmochowski R
    Curr Urol Rep; 2006 Nov; 7(6):462-7. PubMed ID: 17052442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project.
    Welliver C; Feinstein L; Ward JB; Fwu CW; Kirkali Z; Bavendam T; Matlaga BR; McVary KT;
    J Urol; 2020 Jan; 203(1):171-178. PubMed ID: 31430232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.